CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES. (June 2017) - O'Connor, O.A.; Marchi, E.; Kim, W.S.